健帆生物(300529.SZ):擬推2022年股票期權激勵計劃
格隆匯1月17日丨健帆生物(300529.SZ)公佈2022年股票期權激勵計劃(草案),該激勵計劃擬向激勵對象授予802.00萬份股票期權,約佔該激勵計劃草案公吿時公司總股本80549.73萬股的1.00%。
其中首次授予702.00萬份,約佔該激勵計劃草案公吿時公司總股本80549.73萬股的0.87%;預留100.00萬份,約佔該激勵計劃草案公吿時公司總股本80549.73萬股的0.13%,預留部分佔本次授予權益總額12.47%,每份股票期權在滿足行權條件的情況下,擁有在有效期內以行權價格購買1股公司股票的權利。該激勵計劃首次授予的股票期權行權價格為54.77元/份。
該激勵計劃首次授予的激勵對象總人數為735人,包括公司公吿該激勵計劃時在公司(含分公司及控股子公司,下同)任職的董事、高級管理人員、中層管理人員、核心骨幹,不包括獨立董事、監事、和單獨或合計持股5%以上的股東或實際控制人及其配偶、父母、子女。
該激勵計劃有效期自股票期權首次授權之日起至激勵對象獲授的股票期權全部行權或註銷之日止,最長不超過48個月。
公司《2017年股票期權激勵計劃(草案)》《2019年股票期權激勵計劃(草案)》《2019年第二期股票期權激勵計劃(草案)》《2021年限制性股票激勵計劃(草案)》尚在實施中。截至該激勵計劃草案公吿日,公司上述激勵計劃尚未解除限售/歸屬的一類/二類限制性股票數量為749.10萬股,尚未行權的股票期權數量為587.43萬份。公司全部在有效期內的股權激勵計劃所涉及的標的股票總數累計未超過公司股本總額的20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.